ストックスクリーナーアプリを入手
70.03
0.47%
0.33
アフターアワーズ：
69.63
-0.40
-0.57%
Moderna Inc (MRNA) 最新ニュース
Moderna (MRNA) Chief Commercial Officer files baseline Form 3 insider statement - Stock Titan
Is Moderna Stock a No-Brainer Buy After a Key FDA Win? - The Globe and Mail
Is Moderna Stock a No-Brainer Buy After a Key FDA Win? - The Motley Fool
Moderna Inc. mRESVIA targets older adults with a one-dose RSV shot - AD HOC NEWS
ETFs Investing in Moderna, Inc. Stocks - TradingView
mRNA-1273 Linked to Lower COVID-19 Risk Than NVX-CoV2705 - Infectious Disease Advisor
Moderna: Raising Fair Value Estimate Following Science Day That Supports Oncology Pipeline - Morningstar
Moderna Is Applying MRNA Technology in Vaccines, but Also Cancer and Rare Disease Therapies - Morningstar
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines - TradingView
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
MRNA Stock Spikes as Moderna Shares mRNA Pipeline Update - Barchart.com
Stock Of The Day: Will The Moderna Rally Continue? - Benzinga
Moderna (MRNA) Stock Soars 13% on Groundbreaking CAR-T Program Announcement - Blockonomi
Moderna (NASDAQ:MRNA) surge puts stock above most analyst targets ahead of FDA review - TechStock²
Patton Fund Management Inc. Has $4.49 Million Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (MRNA) Stock Analysis: Evaluating the 260% Revenue Growth Amidst a Volatile Market - DirectorsTalk Interviews
Moderna Stock Jumps 12% as Pipeline Reset Puts Aug. 5 FDA Catalyst in Focus - FXLeaders
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA - Stocktwits
Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week - TechStock²
Moderna (MRNA) Stock Soars 13% on In Vivo CAR-T Breakthrough and Flu Vaccine Progress - Blockonomi
SG Americas Securities LLC Sells 27,930 Shares of Moderna, Inc. $MRNA - MarketBeat
The mRESVIA from Moderna Inc.RSV protection moves beyond Covid - Ad-hoc-news.de
S&P 500 ends lower; chips tumble and Moderna rallies - Yahoo Finance
MRNA Stock Surges As Flu Win And Pipeline Shift Grab Attention - timothysykes.com
Wall Street ends mixed; chips tumble and Moderna rallies - marketscreener.com
Trending: Netflix stock bounces back, Moderna surges post–investor day, ON Semi plummets - Yahoo Finance
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism - Invezz
MRNA Maintained by Piper Sandler -- Price Target Raised to $77.0 - GuruFocus
Moderna Shares Up on New Research Efforts for Autoimmune Disorder - WSJ
Wall Street mixed as Moderna rallies and chips tumble - marketscreener.com
Moderna (MRNA) Shares Surge 15% Following Major Business Update - GuruFocus
Why Moderna Is Today’s Top S&P 500 Stock - Barron's
Moderna stock soars 15% as bulls cheer drug pipeline update: Next stop $75? - MSN
Moderna (NASDAQ:MRNA) Reaches New 12-Month HighHere's Why - MarketBeat
Moderna (MRNA) Sees 14.2% Surge, Reaches $68.23 - GuruFocus
Moderna (NASDAQ:MRNA) gains $3.3 billion after CAR-T update - TechStock²
MRNA Stock Jumps As Flu Win And Pipeline Story Heat Up - StocksToTrade
Moderna jumps 12% after investor day - Breakingthenews.net
Moderna highlights expanding mRNA platform at Science Day - Clinical Trials Arena
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? - 24/7 Wall St.
MRNA Stock Jumps As Flu Win And Pipeline Reset Ignite Momentum - timothysykes.com
Moderna stock hits 52-week high at $67.78 By Investing.com - Investing.com Canada
Moderna stock hits 52-week high at $67.78 - Investing.com
Moderna (MRNA) Sees 8.7% Gain, Closing at $64.95 - GuruFocus
Piper Sandler raises Moderna stock price target on pipeline progress - Investing.com
Piper Sandler raises Moderna stock price target on pipeline progress By Investing.com - Investing.com Canada
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms - BioSpace
Moderna shows in vivo CAR-T hand in R&D update - pharmaphorum
Jefferies Adjusts Price Target on Moderna to $53 From $45, Maintains Hold Rating - marketscreener.com
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst - The Globe and Mail
FDA Panel Backs Moderna’s mRNA-Based Influenza Vaccine for Adults 50+ - Infectious Disease Advisor
Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh - TradingView
Moderna, Inc. Stock 12‑Month Price Target Raised to $47.45, Implies 21% Downside - TradingView
Moderna Upbeat on New Flu Shot to Help Educate Public About MRNA - Bloomberg.com
Moderna outlines next phase of mRNA expansion beyond vaccines - The Pharma Letter
Price to book forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Moderna, Inc. Actuals & Estimates (NASDAQ:MRNA) - TradingView
Enterprise value to EBIT forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Moderna Science Day Highlights Expanding Potential of mRNA Platform - Investing News Network
Moderna (MRNA) Unveils Strategic Development Goals at Science Da - GuruFocus
Moderna updates pipeline with CAR-T program for autoimmune diseases By Investing.com - Investing.com Canada
Enterprise value to EBITDA forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Moderna outlines mRNA pipeline progress at Science Day event - StreetInsider
1.73%
1.90%
大文字化:
|
ボリューム (24 時間):